普利製藥(300630.SZ):上半年淨利升31.97%至1.58億元
格隆匯 8 月 26日丨普利製藥(300630.SZ)披露2020年半年度報告,實現營業收入4.02億元,同比增長14.16%;歸屬於上市公司股東的淨利潤1.58億元,同比增長31.97%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.58億元,同比增長35.76%;基本每股收益0.57元。
2020年,公司繼續推行以終端為起點的精細化招商作為主要營銷模式,積極參與國家的“4+7”帶量採購,主動努力做好各省的目錄、物價與招標掛網工作,為銷售做好准入工作。內部加強了組織布局、崗位編制的有效設置與崗位底線的考核、銷售單元開發的考核,嚴格執行預決算制度,在預算與制度框架內展開銷售工作,從而加快利潤的增長。通過營銷模式轉變,降低應收賬款,保證良好的現金流。
公司一直來十分重視藥品的國際化註冊申報,始終堅持藥品雙報的註冊申報方向,藥品的國際化研發與製造保持持續穩定增長,積極拓展海外銷售市場。
2020年公司注射用阿奇黴素、依替巴肽注射液、注射用伏立康唑、注射用萬古黴素、左乙拉西坦注射液、地氯雷他定片、注射用比伐蘆定等產品相繼獲得了國外註冊審批通過,將對公司銷售拓展國外市場都帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.